H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Generate Biomedicines (GENB) to $25 from $16 and keeps a Buy rating on the shares. The company’s GB-0895 is advancing in Phase 3 development, it has two oncology programs entering patient dosing, and a cash runway into the first half of 2028, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GENB:
- Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M
- Generate Biomedicines initiated with a Buy at H.C. Wainwright
- Buy Rating on Generate Biomedicines Driven by Differentiated Pipeline, GB-0895 Asthma Opportunity, and AI-Enabled Protein Platform
- Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating
- Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald